Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities

Bone Marrow Transplantation

Volumn 26, Issue 9, 2000, Pages 985-991

  Furlong, T ^a   Storb, R ^a,b   Anasetti, C ^a,b   Appelbaum, F R ^a,b   Deeg, H J ^a,b   Doney, K ^a,b   Martin, P ^a,b   Sullivan, K ^a,b   Witherspoon, R ^a,b   Nash, R A ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow transplantation; Corticosteroids; Cyclosporine; Graft versus host disease; Leukemia; Tacrolimus

Indexed keywords

BECLOMETASONE; CYCLOSPORIN; METHOTREXATE; MYCOPHENOLIC ACID; PSORALEN; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRIMETREXATE;

ACUTE DISEASE; ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 0033768214     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702639     Document Type: Article

References (52)

1. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
2. Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease
3. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies
4. Analysis of 462 transplantations from unrelated donors facilitated by The National Marrow Donor Program
5. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma
6. A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment
7. A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment
8. Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate
9. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
10. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation
11. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection
12. FK506 'rescue' for resistant rejection of renal allografts under primary cyclosporine immunosuppression
13. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection
14. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation
15. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation
16. Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506)
17. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity
18. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria
19. Toxicity versus rejection- or why conversions between cyclosporine A and FK506 were performed after liver transplantation
20. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors
21. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation
22. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation
23. Phase III study comparing tacrolimus (FK506) with cyclosporine (CSP) for prophylaxis of acute graft-versus-host-disease (GVHD) after marrow transplantation from unrelated donors
24. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis
25. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation
26. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants
27. Phase II study of FK 506 for allogeneic bone marrow transplantation
28. Use of tacrolimus as salvage treatment in steroid-resistant graft versus host disease
29. Bone-marrow transplantation
30. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients
31. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation
32. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome
33. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A
34. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol
35. Cyclosporin A associated seizures in bone marrow transplant recipients
36. Association between cyclosporin neurotoxicity and hypomagnesaemia
37. Cyclosporin A, methylprednisolone, and convulsions
38. Cyclosporin, methylprednisolone, and convulsions
39. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin
40. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study
41. Cyclosporine-associated central nervous system toxicity after allogeneic bone marrow transplantation
42. Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies
43. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation
44. Haemolytic uraemic syndrome after bone marrow transplantation: An adverse effect of total body irradiation?
45. Plasma exchange and vincristine in the treatment of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura associated with bone marrow transplantation
46. Intravascular hemolysis and renal insufficiency after bone marrow transplantation
47. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: Glomerular thromboses and tubular injury
48. Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: Three distinct syndromes
49. Thrombotic microangiopathic syndromes after bone marrow transplantation
50. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation
51. Haemolytic uraemic syndrome during FK506 therapy
52. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506